Akademik Veri Yönetim Sistemi
IMMUNOLOJI ALERJI - ANAFILAKSI, ss.62-67, 2020 (SCI-Expanded)
Use of biological agents (BA) has been a revolution in the treatment of malign and chronic inflammatory diseases. Their use in clinical practice is broadening and parallel to that, hypersensitivity reactions (HSRs) have frequently observed. Patients can develop HSRs to BA during the first lifetime or after repeated exposure. Anaphylaxis is a severe, life-threatening, systemic HSR and its prevalence has increased worldwide. Drugs are among the most common inducer of anaphylaxis. Biological agents are perfect inducer of cellular and humoral mechanisms, in keeping with those BA have been among the mostly cited drugs as causes of drug induced anaphylaxis. Different phenotypes, and potential underlying endotypes, from Type I reactions (IgE/non-IgE-mediated) to cytokine release reactions, with some reactions falling in between both, have been currently defined in anaphylactic reactions to BA. Nevertheless, the underlying mechanisms remain incompletely explained and management should be directed according to the potential underlying mechanisms.